Today's Healthcare Pulse
FDA greenlights durvalumab combo for high‑risk bladder cancer
The FDA approved durvalumab (Imfinzi) combined with Bacillus Calmette‑Guerin for BCG‑naïve, high‑risk non‑muscle invasive bladder cancer. The POTOMAC trial enrolled 1,018 patients and showed a 32% reduction in disease recurrence risk (hazard ratio 0.68, p=0.015). Durvalumab is given at 1,500 mg IV every four weeks for up to 13 cycles.
Also developing:
By the numbers: Apogee Therapeutics raises $1.3B royalty financing
Symptoms of Early Dementia Reversed by Bespoke Treatment Plans
A new personalized approach that targets nutritional gaps, infections, and environmental toxins has shown measurable improvements in memory and daily functioning for people with mild cognitive decline or early‑stage dementia. The bespoke treatment plans combine medical interventions with lifestyle changes after comprehensive assessments. Early results suggest that addressing modifiable risk factors can reverse some dementia symptoms, complementing existing drug therapies such as lecanemab. Researchers propose broader adoption could shift dementia care from symptom management toward reversal.
Radiology Groups Endorse Bill to Exempt Physicians From $100,000 Visa Fee
A bipartisan bill, the H‑1Bs for Physicians and the Healthcare Workforce Act, seeks to exempt physicians and nurses from a newly proposed $100,000 immigration visa fee. The American College of Radiology, American Society of Neuroradiology and more than 40 medical...
Sankofa Village Wellness Center Celebrates Ribbon Cutting
Mayor Brandon Johnson and local officials cut the ribbon on the new Sankofa Village Wellness Center in West Garfield Park. The three‑story, 60,000‑square‑foot hub will deliver primary medical, dental, behavioral, reproductive, substance‑abuse and HIV‑prevention services to roughly 6,000 patients each...
Arrowhead Pharmaceuticals Receives the CHMP’s Positive Opinion for Redemplo (Plozasiran) to Treat Familial Chylomicronemia Syndrome (FCS)
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion on Arrowhead Pharmaceuticals’ RNAi therapy Redemplo (plozasiran) as an adjunct to diet for adults with familial chylomicronemia syndrome (FCS). The recommendation follows the Phase III...
Epigenetic Reset: Once Mocked,
From 2008-2024 I was accused of hyping (a common slur) for suggesting that changes to the epigenome might cause aging and that therapeutics could "allow us to reset the epigenome to a more youthful state." - Oberdoerffer & Sinclair...
Study Finds Children in the US Die at Higher Rates than Peers in Other High-Income Nations
A new study by Children’s Hospital of Philadelphia reveals that U.S. children die at higher rates than peers in 18 other high‑income nations across every age group. The mortality gap first appeared in the early 1950s and has persisted, with...
Former FDA Staffer Cites Political Pressure Blocking Rare‑disease Drug Approval
Former FDA staffer - “I recently left FDA due to the political pressure I was receiving to withhold my recommendation for approval for a drug that was intended for a rare disease. I was part of a review division that...
All of This Has Happened Before
The author compares four high‑profile digital‑health failures—Olive AI, IBM Watson Health, Carbon Health and Babylon Health—to reveal a repeatable playbook of overpromising and underdelivering. In each case, bold claims were funded before any independent proof, with elite investors and government...
Is Health Information Reaching the People Who Need It?
A door‑to‑door survey in the Mississippi Delta revealed that half of residents didn’t know a free‑clinic existed and 80% were unaware of its sliding‑fee scale, illustrating the inverse care law where the most vulnerable miss essential services. The author argues...
South Africa: Investor Consortium Backs Vertice MedTech
A consortium of Amethis, Proparco, ccap.ai and Vertice’s management has completed a new investment in Vertice MedTech Holdings, a South African firm that distributes specialised medical devices and builds digital health solutions. Founded in 2018, Vertice operates two arms—Vertice Healthcare...
Med Ad News Honors Winners of 37th Annual Manny Awards
Med Ad News announced the winners of its 37th Annual Manny Awards at a black‑tie gala in New York. Publicis Health CEO Matt McNally earned Industry Person of the Year after delivering double‑digit growth and investing in health‑specific AI tools....
G2 Speech Achieves Self-Certified Supplier Status on NHS England AVT Registry
G2 Speech has been accepted as a self‑certified supplier on the NHS England Ambient Voice Technology (AVT) Registry. The designation confirms that its SpeechAmbient platform meets NHS safety, data‑security and performance standards. By joining the registry, G2 Speech can more...
Lilly’s CAR-T Devotion; CBER’s Next Top Dog?
Eli Lilly announced the acquisition of Kelonia Therapeutics, an in‑vivo CAR‑T biotech, extending its push into next‑generation cell therapies. The deal follows Lilly’s recent milestone of becoming the first drugmaker to hit a $1 trillion market value, underscoring a diversification strategy that...
The Problem with Psychedelic Research
President Trump signed an executive order to speed the approval of psychedelic drugs for veterans with PTSD and depression, marking the first major regulatory push for these treatments. A new review of 24 studies compared psychedelics to open‑label antidepressants and...
Is Pharma Missing the Boat on Diagnostics?
Pharma giants are accelerating investments in diagnostics to support precision‑medicine strategies, highlighted by Roche's $595 million purchase of SAGA Diagnostics and Abbott's $21 billion acquisition of Exact Sciences. Venture capital for diagnostics lagged behind AI, with only $1.7 billion raised last year versus...
OCR Announces Settlements of Four Ransomware Investigations that Affected Over 427,000 Individuals
The U.S. Department of Health and Human Services Office for Civil Rights announced settlements with four HIPAA‑covered entities after ransomware breaches that exposed the protected health information of more than 427,000 individuals. Regional Women’s Health Group, Assured Imaging, Consociate Health...
Improved Communication of Post-Intensive Care Syndrome Needed
A multi‑institution survey of 382 ICU clinicians and 146 survivors reveals a stark gap between provider awareness of post‑intensive care syndrome (PICS) and patient communication. While 73.8% of clinicians recognize the term, only 16.6% of patients recall being told about...
KT-621 Gets FDA Fast Track Designation for Eosinophilic Asthma
Kymera Therapeutics received FDA fast‑track designation for its oral STAT6 degrader KT‑621, targeting moderate‑to‑severe eosinophilic asthma and atopic dermatitis. The first‑in‑class molecule works intracellularly, offering a potential oral alternative to injectable biologics that block the IL‑4/IL‑13 pathway. Phase 2b trials are...
Sanofi’s Tolebrutinib Gets CHMP Backing for Certain MS Patients Despite FDA Rejection
Sanofi’s BTK inhibitor tolebrutinib received a positive opinion from the European Medicines Agency’s CHMP for treating relapsing forms of multiple sclerosis, despite a complete response letter from the U.S. FDA in December. The CHMP recommendation paves the way for a...
CAR T-Cell Therapy May Prevent Progression of Smoldering Myeloma
A phase‑2 trial of ciltacabtagene autoleucel (cilta‑cel) in 20 high‑risk smoldering multiple myeloma patients achieved a 100% overall response rate, with all participants reaching minimal residual disease negativity within two months and no progression after a median 15.3‑month follow‑up. The...
Heidi Health Enters SA Market as Clinician-Led AI Grows
Heidi, an AI‑driven clinical care platform, has officially launched in South Africa after organically attracting more than 15,000 local clinicians. The service now powers roughly 1.5 million consultations each month, with weekly active usage climbing 500% year‑on‑year. By offering offline‑capable, multilingual...
New Scoring Tool Shows Radiation Can Reprogram Pancreatic Tumor Environment
Researchers at Fox Chase Cancer Center introduced the Harmonic Output of Stromal Traits Factor (HOST‑Factor), a composite scoring system that quantifies the functional state of the pancreatic tumor microenvironment. Using the tool, they showed that pulsed low‑dose‑rate (PLDR) chemoradiation reprograms...
One‑Person Crossover Shows Statin May Impair Workouts
Statin vs Placebo: N = 1 Randomized Crossover Study After posting prior content reviewing data on statins and the potential risk of muscle loss, I was flooded with comments from people saying statins "annihilated" their workouts. Now, I know the party...
Start Lifestyle Changes With GLP‑1, Not After Stopping
The GLP-1 weight regain studies everyone is citing have a quiet design flaw: in a lot of those trials, patients were put on a rigid reduced-calorie plan while on the drug, then told to keep following that same rigid plan...
A Deeper Dive on the Cancelation of the Flu Shot Mandate in the Military—It’s Not All Roses and Champagne
The Pentagon has rescinded the mandatory flu‑shot policy for service members, but the cancellation order includes a 15‑day window for each branch to petition for exemptions. This means commanders could reinstate the requirement for specific units, such as ship crews...
Oracle AI Cuts AtlantiCare Documentation Time by 40%
With Oracle AI Agents, the @AtlantiCareNJ team can transform their clinical operations, staffing, patient engagement, and more. @OracleHealth Clinical AI Agent is already helping them reduce documentation time by 40%—looking forward to more stories like these. https://t.co/YBqTaTyUOV
WHO Marks 40 Years of Ottawa Charter, Calls for Health‑Promotion Reboot in Europe
The World Health Organization convened a two‑session virtual dialogue to commemorate the Ottawa Charter’s 40th anniversary, urging European nations to overhaul health‑promotion policies amid rising non‑communicable disease deaths and climate‑driven health threats.
The CMS-FDA RAPID Coverage Pathway Is a Capital Markets Event Disguised as a Coverage Policy: What the Regulatory-Reimbursement Clock Synch...
On April 23, 2026 CMS and the FDA unveiled the RAPID coverage pathway, a joint program that synchronizes Medicare reimbursement with FDA market authorization for breakthrough Class II and Class III devices. Under RAPID, a proposed national coverage determination is issued the...
Are ‘Forever Chemicals’ Aging You? New Research Raises Concerns for Men
Researchers analyzing U.S. NHANES data found that two newer PFAS chemicals—perfluorononanoic acid (PFNA) and perfluorooctanesulfonamide (PFOSA)—are linked to accelerated epigenetic aging in men aged 50 to 64. The compounds were present in 95% of participants, but only men showed a...
Orthopedic Care Draws in PE: 6 Deals
Private‑equity firms are increasingly targeting the orthopedic sector, with six deals announced this year. Archimed, Cinven, Gemspring and InTandem are among the investors, collectively committing roughly $1.2 billion. The transactions span traditional device manufacturers, joint‑replacement joint ventures, and emerging digital orthopedics...
Why Accountability in Medicine Must Guide Health Care AI
Healthcare AI is exploding, with ambient scribes and large‑language‑model chatbots promising faster documentation and patient interaction. Yet the authors argue that accuracy alone is insufficient; without built‑in accountability, harmful errors become opaque. They call for a shift from generative AI...
Pfizer’s Strategy Chief Andrew Baum Steps Down; Helus Pharma Swaps Out CEO After Two Months
Andrew Baum, former Citi analyst and Pfizer's chief strategy and innovation officer, has left his executive role but will stay on as a senior strategic advisor to CEO Albert Bourla. His exit adds to a recent series of senior departures...
BIO Is Expanding Its Work to Defend IP
The Biotechnology Innovation Organization (BIO) is scaling its intellectual‑property advocacy by creating an IP Task Force and a new Economic Growth, Innovation, and Intellectual Property Committee to steer strategy. BIO is actively lobbying on Capitol Hill, filing amicus briefs, and...
Concierge Medicine Was Built For The Few. Here’s How To Open It To The Many
Concierge and direct primary care models, long limited to affluent patients, are gaining traction as a solution to primary‑care capacity constraints. The Centers for Medicare & Medicaid Services introduced Advanced Primary Care Management (APCM) codes in January 2025, offering per‑patient,...
Swedish Study Shows Fathers' Risk of Depression Jumps 30% One Year After Birth
Researchers in Sweden analyzed more than one million fathers and found that, while psychiatric diagnoses dip during pregnancy, rates of depression and stress‑related disorders surge by over 30% when the child turns one. The findings, published in JAMA Network Open,...
FEMA Approves More Than $657 Million to Reimburse States, Medical Facilities for Backlog of Public Assistance
The Department of Homeland Security announced that FEMA will disburse more than $657 million to clear a backlog of COVID‑19 public‑assistance reimbursements. The money will flow through FEMA’s Public Assistance program to fund 75 projects across states, territories and health‑care facilities....
Why Ancestry Matters in the Cardiac Screening of Elite Soccer Players
A new ESC Preventive Cardiology study examined 9,024 elite male soccer players screened between 2017 and 2024, finding that 25% identified as Black and that cardiac abnormalities varied markedly by regional ancestry. West and Central African players displayed the highest...
Fragmentation Fuels Distrust of Health Sector
The 2026 Edelman Trust Barometer’s Special Report on Health reveals deep fragmentation in U.S. health discourse, with 86% of respondents seeing the sector as divided. Trust in the healthcare system has slipped, and confidence in media reporting on health dropped...
Real‑time CGM Cuts HbA1c in Large Type 2 Diabetes Trial
Researchers led by Dr. Emma Wilmot and Dr. Lala Leelarathna reported that real‑time continuous glucose monitoring (CGM) significantly improved glycemic outcomes for 303 adults with type 2 diabetes on basal insulin, outperforming traditional finger‑prick testing. The findings, published in The Lancet...
Why Are Medical Aid Members Facing More Out-of-Pocket Healthcare Expenses
South African medical scheme members are increasingly hit with out‑of‑pocket costs because schemes reimburse only their own tariff rates while specialists often charge far more, sometimes up to five times the scheme rate. Rising medical inflation—about 9‑10% annually versus 4‑5%...
Trump Administration Secures Regeneron Deal to Slash Medicaid Drug Prices, Cuts Praluent to $225
President Donald Trump announced a deal with Regeneron that will lower the cholesterol drug Praluent to $225 on the new TrumpRx portal and extend price cuts to all current and future Regeneron drugs on Medicaid. The agreement also includes a...
Mabwell Initiates P-III Trial for 9MW2821 in TNBC
Mabwell has launched a Phase III trial of its Nectin‑4‑targeting antibody‑drug conjugate 9MW2821 in patients with locally advanced or metastatic triple‑negative breast cancer (TNBC). The study pits 9MW2821 against the investigator’s choice of chemotherapy in patients who have already received taxane‑based...
VA’s $10 Billion EHR Swap Falters, Highlighting Enterprise Health‑IT Risks
The U.S. Department of Veterans Affairs’ $10 billion contract to replace its home‑grown VistA system with Oracle‑Cerner’s electronic health record has reached only 10 hospitals—6% of the network—after eight years. The stalled deployment has driven staff turnover, a GAO warning, and...
CommonSpirit Health CMO Adam Rice Tackles AI Misinformation to Safeguard Brand Trust
Adam Rice, chief marketing officer of CommonSpirit Health, announced a coordinated effort to combat AI‑generated misinformation that threatens the health system’s brand reputation. The initiative, unveiled at a Newsweek webinar, aims to regain control of the first‑point‑of‑contact experience for more...
FDA Declines to Approve AbbVie's Botox Follow-Up
The FDA sent a complete response letter to AbbVie, rejecting its filing for TrenibotE, a rapid‑acting, shorter‑duration botulinum toxin intended as a follow‑up to Botox. The agency’s concerns focus on manufacturing data rather than safety or efficacy, and AbbVie says...
A Watershed Event.
The FDA approved Regeneron’s gene therapy that restores hearing in children born deaf, with the company pledging free access. At the same time, Anthropic unveiled Mythos, an AI model that autonomously discovers and exploits software vulnerabilities, prompting the U.S. to...
UK Biobank Data of 500,000 Volunteers Listed for Sale on Alibaba
UK Biobank’s de‑identified health and genetic data for 500,000 volunteers appeared on the Chinese e‑commerce platform Alibaba. The breach, traced to three Chinese research institutions, prompted a parliamentary briefing, a temporary shutdown of the Biobank’s research platform, and renewed calls...
Vistin Pharma ASA Reports Q1 Earnings Dip as European Market Pressures Persist
Vistin Pharma ASA announced first‑quarter earnings of NOK21.49 million, down 0.9% from a year earlier, while revenue fell 2.5% to NOK112.21 million. The results reflect tightening reimbursement environments and competitive pressure across Europe’s pharmaceutical sector.
The Ron Lanton Report: Where Innovations Happen
Ron Lanton’s latest report argues that geography has become a primary strategic lever in healthcare, shaping where products are developed, manufactured, priced, and sustained. Policy signals, trade dynamics, and infrastructure constraints now sit at the front of the decision tree,...
Therapy Company Mixes Emotional and Artificial Intelligence to Top Ranking
Grow Therapy, founded in 2020, has vaulted to the top of the FT/Statista Fastest‑Growing Companies 2026 list with a 455.6% compound annual growth rate, expanding revenue from $3.6 million in 2021 to $617.4 million in 2024. The company leverages AI‑enhanced chat tools...